Suy giảm miễn dịch kết hợp nặng: sự sống sót được cải thiện dẫn đến phát hiện bệnh gan tiềm ẩn

Cagdas D, Gur Cetinkaya P, Karaatmaca B, et al. ADA Deficiency: evaluation of the Clinical and Laboratory features and the Outcome. J Clin Immunol. 2018;38:484–93.

Nyhan WL. Disorders of purine and pyrimidine metabolism. Mol Genet Metab. 2005;86:25–33.

Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.

Whitmore KV, Gaspar HB. Adenosine Deaminase Deficiency - more than just an immunodeficiency. Front Immunol. 2016;7:314.

Cederbaum SD, Kaitila I, Rimoin DL, et al. The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency. J Pediatr. 1976;89:737–42.

Hirschhorn R, Paageorgiou PS, Kesarwala HH, et al. Amerioration of neurologic abnormalities after “enzyme replacement” in adenosine deaminase deficiency. N Engl J Med. 1980;303:377–80.

Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr. 2004;144:278–80.

Bollinger ME, Arredondo-Vega FX, Santisteban I, et al. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med. 1996;334:1367–71.

Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35.

Rosenberg HK, Markowitz RI, Kolberg H, et al. Normal splenic size in infants and children: sonographic measurements. AJR Am J Roentgenol. 1991;157:119–21.

Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

Vehmas T, Kaukiainen A, Luoma K, et al. Liver echogenicity: measurement or visual grading? Comput Med Imaging Graph. 2004;28:289–93.

Hershfield M. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. The metabolic and molecular basis of inherited disease. 1995;1725.

Kredich Nt, Hershfield M. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. Metabolic basis of inherited disease/[edited by] John B Stanbury[et al]; 1983.

Migchielsen AA, Breuer ML, van Roon MA, et al. Adenosine–deaminase–deficient mice die perinatally and exhibit liver–cell degeneration, atelectasis and small intestinal cell death. Nat Genet. 1995;10:279–87.

Wakamiya M, Blackburn MR, Jurecic R, et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci U S A. 1995;92:3673–7.

Ratech H, Greco MA, Gallo G, et al. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol. 1985;120:157–69.

Tsai S, Clemente-Casares X, Zhou AC, et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 2018;28:922–34. e4.

Edgerton DS, Cardin S, Emshwiller M, et al. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes. 2001;50:1872–82.

Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol. 2013;33:748–58.